On Tuesday, October 11, I Bought 30 shares of AbbVie Inc. at $ 62.98 per share plus commission.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinsons disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company is headquartered in North Chicago, Illinois and was spun off from Abbott Laboratories (ABT) in January 2013.
After spinning off AbbVie has increased dividends for four years now. ABBV now pays dividends of $ 0.57 per share normally in February, May, August and November.
If you are interested, you can read D4L's dividend stock analysis of the AbbVie here.
Details of my purchase:
Some ratings for ABBV:
Yahoo: Mean Recommendation 2.3, 1y Target Est $ 71.28
Reuters: Mean Rating 2.29
At today's exchange rate, this purchase 30 shares of ABBV will increase € 46.20 ($ 50.96) of my expected annual net dividend income and will increase my portfolio's projected annual net dividend income to € 9,400.00. With purchase price $ 62.98 plus commission ($ 5.00) my starting yield on cost is 3.61%.
Click here to see my portfolio.
Full Disclosure: Long ABBV
Thanks for stopping by!